DiaMedica Therapeutics (DMAC) Change in Accured Expenses (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Change in Accured Expenses for 9 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 496.95% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $823000.0 (up 90.07% YoY), and the FY2025 full-year result was -$892000.0, down 135.84% from the prior year.
• Change in Accured Expenses rose to $1.3 million in Q2 2026 per DMAC's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.3 million in Q2 2026 and bottomed at -$1.3 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $132388.9 across 5 years, with a median of $118000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 936.84% in 2024, then plunged 7021.05% in 2025.
• Over 5 years, Change in Accured Expenses stood at $737000.0 in 2022, then dropped by 28.09% to $530000.0 in 2023, then jumped by 145.47% to $1.3 million in 2024, then plunged by 78.32% to $282000.0 in 2025, then soared by 361.7% to $1.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $1.3 million, -$1.2 million, and $282000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.